Clinical trials: MTOR
Polycystic Kidney, Type 1 Autosomal Dominant Disease, Polycystic Kidney, Type 2 Autosomal Dominant Disease
Pulsed Oral Sirolimus in Autosomal Dominant Polycystic Kidney Disease
Sirolimus (SIR) has lead to a reduction of overall kidney size, a decrease in cyst density and general tubular cell proliferation in animal models, and to a reduction of the increase in creatinine and blood urea nitrogen by 34…
- Trial name
- RAP (NCT02055079)
- Testing
- Sirolimus
- Where
- Austria
- Volunteers
- 68 people
- Sponsor
- Medical University of Vienna
Malignant Mesothelioma
S0722: Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well everolimus works in treating patients with pleural malignant…
- Trial name
- NCT00770120
- Testing
- everolimus
- Where
- 129 sites in United States
- Volunteers
- 61 people
- Sponsor
- SWOG Cancer Research Network
Neoplasm
A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)
This study will evaluate PF-05212384 (gedatolisib) PI3K/mTOR inhibitor)) in combination with either docetaxel, cisplatin or dacomitinib in select advanced solid tumors.
- Trial name
- NCT01920061
- Testing
- PF-05212384 (gedatolisib), Docetaxel, Cisplatin
- Where
- 29 sites in United States, Canada and 3 more
- Volunteers
- 110 people
- Sponsor
- Pfizer
Solid Tumor, Adult, NSCLC
Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer With a KRAS G12C Mutation (KRYSTAL -19)
This study will evaluate the safety, MTD and/or RP2D, PK, and clinical activity of the combination of adagrasib with nab-sirolimus in patients with advanced solid tumors/NSCLC with a KRAS G12C mutation.
- Conditions
- Solid Tumor, Adult, NSCLC, Advanced Cancer, Metastatic Cancer
- Trial name
- NCT05840510
- Testing
- Adagrasib, nab-Sirolimus
- Where
- 3 sites in United States
- Volunteers
- 6 people
- Sponsor
- Mirati Therapeutics Inc.
HR+ HER2- Breast Cancer
Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer
The study is a Phase 1b/2, multi-center, open-label, dose escalation trial evaluating the safety and preliminary efficacy of sapanisertib and serabelisib (PIKTOR) with fulvestrant and/or other anticancer therapies in participants…
- Trial name
- NCT07558733
- Testing
- Serabelisib, Sapanisertib, Fulvestrant
- Where
- 7 sites in United States
- Volunteers
- 32 people
- Sponsor
- Faeth Therapeutics
Breast Neoplasms
Everolimus in Breast Cancer Patients After Pre-operative Chemotherapy
This is a randomized controlled pilot study investigating signals involved in drug resistance to chemotherapy. Patient will be randomized to undergo observation or to receive Everolimus after completion of neoadjvuant treatment…
- Trial name
- NCT01088893
- Testing
- Everolimus
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Organisation for Oncology and Translational Research
Posttraumatic Stress Disorder
Rapamycin as a Means of Interference With Reconsolidation of Posttraumatic Stress Disorder-related Traumatic Memory
The purpose of the proposed study is to determine if pairing reactivation of a traumatic memory with a single administration of Rapamycin (e.g., Sirolimus) in men with combat-related Posttraumatic Stress Disorder leads to a…
- Trial name
- NCT01449955
- Testing
- Rapamycin
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- University of Texas Southwestern Medical Center
Kidney Cancer
Everolimus and Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer
RATIONALE: Everolimus and imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Everolimus may also block blood flow to the tumor.
- Trial name
- NCT00331409
- Testing
- Everolimus, imatinib mesylate
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- OHSU Knight Cancer Institute
Neurofibromatosis Type 1
A Phase II Study of the mTOR Inhibitor Sirolimus in Neurofibromatosis Type 1 Related Plexiform Neurofibromas
Treatment Overview This phase II study will evaluate the activity of sirolimus in children and adults with NF1 and inoperable plexiform neurofibromas that have the potential to cause significant morbidity.
- Trial name
- Protocol 102 (NCT00634270)
- Testing
- Sirolimus
- Where
- 9 sites in United States
- Volunteers
- 58 people
- Sponsor
- University of Alabama at Birmingham
ADPKD
The Vienna RAP Pilot Study
The purpose of this study is to evaluate the safety of a daily single oral dose of sirolimus in patients with advanced autosomal dominant polycystic kidney disease.
- Trial name
- RAP (NCT01632605)
- Testing
- Sirolimus
- Where
- Austria
- Volunteers
- 8 people
- Sponsor
- Medical University of Vienna
Kaposiform Hemangioendotheliomas, Tufted Angioma
Safety and Efficacy Study of Sirolimus in Complicated Vascular Anomalies
The purpose of this study is to determine if the use of sirolimus in the treatment of children and young adults with complicated vascular anomalies will prove to be safe and provide objective response resulting in improved…
- Conditions
- Kaposiform Hemangioendotheliomas, Tufted Angioma, Capillary Venous Lymphatic Malformation, Venous Lymphatic Malformation
- Trial name
- NCT00975819
- Testing
- sirolimus
- Where
- 2 sites in United States
- Volunteers
- 61 people
- Sponsor
- Denise Martin Adams
Neurofibromatosis 2, Meningioma
AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas
The goal of this clinical research study is to learn if the study drug AZD2014 can shrink growing or symptomatic meningiomas.
- Trial name
- NCT02831257
- Testing
- AZD2014
- Where
- 2 sites in United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Hematologic Malignancies, Leukemia
Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED)
The purpose of this phase II study is to assess the efficacy of AP23573 in patients with specified relapsed or refractory hematological malignancies.
- Conditions
- Hematologic Malignancies, Leukemia, Myelodysplastic Syndromes, Myeloid Metaplasia
- Trial name
- NCT00086125
- Testing
- ridaforolimus
- Where
- 8 sites in United States
- Volunteers
- 57 people
- Sponsor
- Merck Sharp & Dohme LLC
Kidney Transplant, Adult Living Donor Kidney Transplant Recipients
Treg Therapy in Subclinical Inflammation in Kidney Transplantation
The purpose of this study is: To see if polyTregs can reduce inflammation in a transplanted kidney. To find out what effects, good or bad, polyTregs will have in the kidney recipient.
- Conditions
- Kidney Transplant, Adult Living Donor Kidney Transplant Recipients, Renal Transplant, Living Kidney Donor
- Trial name
- TASK (NCT02711826)
- Testing
- Polyclonal Regulatory T Cells, Everolimus, Tacrolimus
- Where
- 6 sites in United States
- Volunteers
- 32 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Meningioma
Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas
This research study is studying a chemotherapy as a possible treatment for Meningiomas (recurrent). The study intervention involved in this study is: --AZD2014 (vistusertib)
- Trial name
- NCT03071874
- Testing
- AZD2014
- Where
- 3 sites in United States
- Volunteers
- 28 people
- Sponsor
- Massachusetts General Hospital
Kaposi Sarcoma
A Phase II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation of Oral mTOR-inhibitor Everolimus (RAD001) 10 mg Daily in Patients Suffering From Classic or Endemic Kaposi's Sarcoma
Classic Kaposi's sarcoma (CKS) is an angioproliferation associated with human herpes virus 8 (HHV8), which sometimes requires systemic treatment. Rapamycin and everolimus are mTOR inhibitors.
- Trial name
- NCT01412515
- Testing
- everolimus
- Where
- France
- Volunteers
- 11 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Recurrent Non-small Cell Lung Cancer, Squamous Cell Lung Cancer
Sirolimus and Gold Sodium Thiomalate in Treating Patients With Advanced Squamous Non-Small Cell Lung Cancer
This phase I trial studies the side effects and best dose of sirolimus and gold sodium thiomalate when given together in treating patients with advanced squamous non-small cell lung cancer (NSCLC).
- Conditions
- Recurrent Non-small Cell Lung Cancer, Squamous Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
- Trial name
- NCT01383668
- Testing
- sirolimus, gold sodium thiomalate, pharmacological study
- Sponsor
- Mayo Clinic
Advanced Solid Cancers
A Study of the mTOR Inhibitor Rapamycin (Rapamune, Sirolimus) in Combination With Abraxane in Advanced Solid Cancers
Rapamycin is a drug that has been approved by the Food and Drug Administration (government) for use in patients receiving a kidney transplant to prevent the patient's body from rejecting the transplanted kidney.
- Trial name
- NCT00337376
- Testing
- Rapamune, Abraxane
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Yale University
Tuberous Sclerosis, Lymphangioleiomyomatosis
Trial of Efficacy and Safety of Sirolimus in Tuberous Sclerosis and LAM
The purpose of this study is to determine the safety and efficacy of the mTOR inhibitor sirolimus as a treatment for renal angiomyolipomas in patients with tyberous sclerosis complex or sporadic lymphangioleiomyomatosis.
- Trial name
- TESSTAL (NCT00490789)
- Testing
- sirolimus
- Where
- 3 sites in United Kingdom
- Volunteers
- 14 people
- Sponsor
- Cardiff University
Locally Advanced Bladder Urothelial Carcinoma, Metastatic Transitional Cell Carcinoma
Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations
This pilot phase II trial studies how well sapanisertib works in treating patients with bladder cancer that has spread from where it started to nearby tissue or lymph nodes (locally advanced) or other places in the body…
- Conditions
- Locally Advanced Bladder Urothelial Carcinoma, Metastatic Transitional Cell Carcinoma, Metastatic Urothelial Carcinoma, Recurrent Bladder Carcinoma
- Trial name
- NCT03047213
- Testing
- Sapanisertib
- Where
- 20 sites in United States
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)